News

Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...
Bristol Myers Squibb Co. closed 20.32% short of its 52-week high of $63.33, which the company achieved on March 11th.
With data as of April 9, 2025, we examine if Bristol-Myers Squibb Company(BMY) is consistently building momentum based on ...
Bristol-Myers Squibb Company (BMY) is currently at $50.78, down $2.96 or 5.5% --Would be lowest close since Sept. 26, 2024, when it closed at $50.12 --On pace for largest percent decrease since April ...
Bearish flow noted in Bristol Myers ( BMY) Squibb with 7,624 puts trading, or 1.4x expected. Most active are 5/2 weekly 50 puts and May-25 65 calls, with total volume in those strikes near 5,500 ...
The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...
To name a few, Johnson & Johnson, Merck & Co., and Bristol Myers Squibb are all top NJ-based industry names with broad export footprint in China.
Artificial intelligence is increasingly becoming a cornerstone in pharmaceutical research, with numerous companies leveraging advanced algorithms to expedite drug discovery and development. This ...